MBX Microbix Biosystems

Microbix Schedules Release of Results for Q2 Fiscal 2025

Microbix Schedules Release of Results for Q2 Fiscal 2025

Results Release and Webinar Discussion on Morning of May 15, 2025

MISSISSAUGA, Ontario, May 08, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it expects to file the financial statements, management disclosure and analysis, and results news release for its second quarter of fiscal 2025 ended March 31, 2025 (“Q2 2025”) prior to the start of trading on May 15, 2025. At 11:00 AM ET on that day, Microbix intends to hold a webinar discussion of Q2 2025 results with its CEO, CFO, and COO.

Investor and shareholders can participate in the webinar, hosted by Adelaide Capital, by registering at: .

It will also be live-streamed to YouTube at: .

Telephone participation in the webinar can be arranged by contacting Microbix or Adelaide Capital at the contact numbers provided at the end of this news release.

A replay of the webinar will also be made available on Adelaide Capital’s YouTube channel.

About Microbix Biosystems Inc.

Microbix Biosystems Inc. creates proprietary biological products for human health, with over 120 skilled employees and revenues now targeting C$ 2.0 million per month. It enables the worldwide commercialization of diagnostic assays by making a wide range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs™) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its antigens drive the antibody tests of approximately 100 diagnostics makers, while QAPs are sold to clinical lab accreditation organizations, diagnostics companies, and clinical labs. Microbix QAPs are now available in over 30 countries, supported by a network of international distributors. Microbix is ISO 9001 & 13485 accredited, U.S. FDA registered, Australian TGA registered, Health Canada establishment licensed, and provides IVDR-compliant CE marked products.

Microbix also applies its biological expertise and infrastructure to develop other proprietary products and technologies, most notably Kinlytic® urokinase, a biologic thrombolytic drug used to treat blood clots, and reagents or media to support molecular diagnostic testing (e.g., its DxTM™ for patient-sample collection). Microbix is traded on the TSX and OTCQX, and headquartered in Mississauga, Ontario, Canada.

Forward-Looking Information

This news release includes “forward-looking information,” as such term is defined in applicable securities laws. Forward-looking information includes, without limitation, expected timing of release of financial results, intended discussion of financial results or the outlook for the business, risks associated with its financial results and stability, its current or future products, development projects such as those referenced herein, access to and sales to foreign jurisdictions, engineering and construction, production (including control over costs, quality, quantity and timeliness of delivery), foreign currency and exchange rates, maintaining adequate working capital and raising further capital on acceptable terms or at all, and other similar statements concerning anticipated future events, conditions or results that are not historical facts. These statements reflect management’s current estimates, beliefs, intentions, and expectations; they are not guarantees of future performance. The Company cautions that all forward-looking information is inherently uncertain, and that actual performance may be affected by many material factors, some of which are beyond the Company’s control. Accordingly, actual future events, conditions and results may differ materially from the estimates, beliefs, intentions, and expectations expressed or implied in the forward-looking information. All statements are made as of the date of this news release and represent the Company’s judgement as of the date of this new release, and the Company is under no obligation to update or alter any forward-looking information.

Please visit or for recent Microbix news and filings.

For further information, please contact Microbix at:

Cameron Groome,

CEO

(905) 361-8910
Jim Currie,

CFO

(905) 361-8910
Deborah Honig,

Investor Relations

Adelaide Capital Markets

(647) 203-8793

Copyright © 2025 Microbix Biosystems Inc.

Microbix®, DxTM™, Kinlytic®, & QAPs™ are trademarks of Microbix Biosystems Inc.



EN
08/05/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Microbix Biosystems

 PRESS RELEASE

Microbix Schedules Release of Results for Q2 Fiscal 2025

Microbix Schedules Release of Results for Q2 Fiscal 2025 Results Release and Webinar Discussion on Morning of May 15, 2025 MISSISSAUGA, Ontario, May 08, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it expects to file the financial statements, management disclosure and analysis, and results news release for its second quarter of fiscal 2025 ended March 31, 2025 (“Q2 2025”) prior to the start of trading on May 15, 2025. At 11:00 AM ET on that day, Microbix intends to hold a webi...

 PRESS RELEASE

Microbix’s Clot-Buster Drug Project Advances

Microbix’s Clot-Buster Drug Project Advances Sequel Pharma Executes Agreement with CDMO for Drug Product Manufacturing MISSISSAUGA, Ontario, May 05, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that its funding and commercialization partner, Sequel Pharma, LLC (“Sequel”), has executed an agreement with a leading international contract development and manufacturing organization (“CDMO”) for production of the formulated and packaged drug (i.e., “Drug Product”) of Kinlytic® urokinase ...

 PRESS RELEASE

Microbix Presenting at the 2025 Bloom Burton Conference

Microbix Presenting at the 2025 Bloom Burton Conference MISSISSAUGA, Ontario, May 01, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces it will be attending and presenting at the 2025 Bloom Burton & Co. Healthcare Investor Conference (the “Conference”) taking place at the Metro Toronto Convention Centre, North Building, on Monday and Tuesday, May 5 & 6, 2025. The Conference provides Microbix the opportunity to build connections with Canadian, U.S., and international investors focused...

 PRESS RELEASE

Microbix Exhibiting at ESCMID Global 2025

Microbix Exhibiting at ESCMID Global 2025 Microbix Showcasing novel QAPs, Customer Presenting Pilot EQA Program Results MISSISSAUGA, Ontario, April 09, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it will be attending and exhibiting at ESCMID Global 2025 and that a customer and collaborator will be presenting results of a pilot External Quality Assessment (EQA) program enabled by Microbix Quality Assessment Products (QAPs™). ESCMID Global is the Congress of the European S...

 PRESS RELEASE

Microbix Provides Business Updates

Microbix Provides Business Updates U.S. & Reciprocal Tariff Outcomes, Second-Half 2025 Outlook MISSISSAUGA, Ontario, April 08, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF) (“Microbix®” or the Company”), a life sciences innovator, manufacturer, and exporter, provides an update on U.S. and reciprocal tariff outcomes as well as business conditions and its outlook for the balance of its fiscal 2025. As has been widely reported, on April 2 the United States government imposed tariffs on certain goods (i.e., steel, aluminum, & automobiles) being imported into th...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch